DNAe Early Access Program
Join the forefront of innovation in NGS clinical diagnostics.
DNAe is developing a rapid, point-of-need Next Generation Sequencing (NGS)-based diagnostic platform, LiDia-SEQ™. The LiDia-SEQ™ platform is a first of its kind platform enabling raw sample-to-sequencing results in a single platform – delivering results in just a few hours, running within a fully automated workflow optimized for non-specialist users.
The flagship test on the platform is the BSI/AMR Test. The whole blood sample test allows the detection of bacterial and fungal pathogens, along with key antimicrobial resistance markers for bacterial pathogens.
The BSI/AMR test can identify target microorganisms at very low concentrations of ≤3 CFU/mL and associated AMRs directly from a whole blood sample. The initial test is expected to offer a comprehensive testing menu of ~7,200 bacteria, with ~ 30 associated AMRs, and ~750 fungi. This breakthrough test will be the first to be commercially launched and is intended for use in patients suspected of having bloodstream infections/sepsis.
DNAe Early Access Program (EAP): Opportunity for clinical partners
The LiDia-SEQ™ platform is at an advanced stage of development, and DNAe is now inviting applications from hospitals to participate in our Early Access Program – offering exclusive access to the proprietary technology at the core of the BSI/AMR test.
The goal is to run collaborative research studies investigating current areas of interest and/or challenge, and to generate and publish high-quality, high-impact data which demonstrates the performance, value proposition and models the health economic benefits of the BSI/AMR test on the LiDia-SEQ™ platform. Potential areas of study could include comparison of BSI/AMR test versus the standard of care (blood culture) and currently available clinical tests, use of the BSI/AMR test for healthcare-associated infections (HAIs), infection prevention and control (IPC) and outbreak identification and response, amongst others.
EAP Phase One
Phase One of DNAe’s Early Access Program includes exclusive access to the BSI/AMR assay (the bench version of the BSI/AMR test), with program participants able to send whole blood samples and culture isolates to DNAe for testing.
DNAe will test the samples free of charge and report a test result (provided for research use only). The intended start date for Phase One is March 2026, and DNAe will be engaging with potential participant sites starting in October 2025.
EAP Phase Two
The second phase of the program will involve placement of prototype LiDia-SEQ™ systems in select hospitals prior to product launch, to be used for running DNAe’s BSI/AMR test within the hospital. The timeline for Phase Two is TBC.
Why Join?
- Exclusive early access to ground-breaking technology before general release
- Collaborate directly with our development team to shape final features
- Gain visibility as a pioneering site for next-generation healthcare innovation
Who Should Apply?
- Hospitals, clinics and research institutions focused on infectious disease, oncology or critical care
- Teams committed to testing new diagnostic tools and advancing the adoption of innovative diagnostic solutions
- Partners eager to co-develop and validate real-world applications
Program Highlights
- Limited enrollment: early adopter partners
- Hands-on testing and feedback cycles
- Recognition in future research publications and case studies
Key Timelines
- October 2025: Expressions of interest and engagement with potential participating hospitals
- March 2026: Start of EAP Phase One testing on whole blood samples and culture isolates
- TBC 2026: Prototype LiDia-SEQ™ systems placed in select hospitals to run BSI/AMR test
